**RESEARCH**

**Effect of mast cell stabilization on angiogenesis in primary and secondary experimental *Trichinella spiralis* infection**

Marwa A. EL-Dardiry$^{1,}$* Amany A. Abdel-Aal$^{2,3}$, Magda S. A. Abdeltawab$^2$, Mona El-Sherbini$^2$, Marwa A. Hassan$^2$, Asmaa A. Abdel-Aal$^4$, Manal Badawi$^5$, Shady E. Anis$^6$, Bahaa-Eldin A. Khaled$^{7,8}$ and Abeer S. Al-Antably$^2$

**Abstract**

**Background:** Mast cells are known to affect the primary and secondary immune responses against parasites, and this effect is partially mediated through the release of pro-angiogenic mediators. The aim of this study was to explore the effect of the mast cell stabilizer (MCS), ketotifen, with and without albendazole, an anti-parasitic prescription medicine, on the inflammatory response against *Trichinella spiralis*, with the overall aim to investigate its effect on angiogenesis accompanying nurse cell formation.

**Methods:** The effect of ketotifen and albendazole was explored in eight groups of female BALB/c mice. Four groups were sensitized with a small dose of *T. spiralis* larvae. The drug regimen was then applied to both sensitized (challenged) and non-sensitized mice. The parasite load was assessed by histopathological examination of the small intestine and muscle tissue, and angiogenesis was assessed by immunohistochemistry to determine the expression of vascular endothelial growth factor (VEGF).

**Results:** Sensitized mice showed a significantly lower parasite load and a more pronounced inflammatory response than mice receiving a single infective dose of *T. spiralis* larvae. All treated groups showed a significant reduction in parasite count compared to the control groups (groups Ia and Ib), reaching approximately an 98.8% reduction in adult parasite count in the sensitized group treated with albendazole (groups IIa and IIB). MCS significantly decreased the parasite count during both the intestinal or muscular phases, reduced tissue inflammation, and decreased local VEGF expression, both in the non-sensitized and sensitized groups.

**Conclusion:** Sensitization with a low dose of *T. spiralis* larvae was found to confer a partial protective immunity against re-infection and to positively affect the study outcomes, thus underlining the importance of vaccination, but after extensive studies. The anti-angiogenic effect of MCS protects against larval encystation during the muscle phase. The anti-angiogenic potential of albendazole suggests that the action of this anti-helminthic during trichinellosis is not confined to structural damage to the parasite cuticle but includes an effect on host immunopathological response.

**Keywords:** *T. spiralis*, Mast cells, Ketotifen, Albendazole, Angiogenesis, VEGF

*Correspondence: marwaahmed2008@outlook.com
1 Department of Medical Parasitology, Faculty of Medicine, Fayoum University, Fayoum, Egypt
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Graphical Abstract

a

Infected with *T. spiralis* non-treated
Control group
A: Non-sensitized

Infected treated

Albendazole

MCS

Albendazole + MCS

Larval reduction: 94.51 %
VEGF count: 7.5
Inflammation: Moderate

Larval reduction: 56.0 %
VEGF count: 0
Inflammation: Mild

Larval reduction: 99.5 %
VEGF count: 0
Inflammation: V. mild

b

B: Sensitized

Intra cystic inflammatory Cs

Larval reduction: 76.44 %
VEGF count: 22.5
Inflammation: Severe

Larval reduction: 93.0 %
VEGF count: 4
Inflammation: Moderate

Larval reduction: 44.2 %
VEGF count: 0
Inflammation: Mild

Larval reduction: 97.7 %
VEGF count: 0
Inflammation: V. mild
Background

*Trichinella* infection in humans and animals results from the ingestion of first-stage larvae in uncooked or under-cooked meat, with the most notorious sources being pork and the meat of animals such as bears. *Trichinella spiralis* was the first species to be discovered [10], and it is also the most virulent and pathogenic species to humans. Its higher pathogenicity, compared to that of other *Trichinella* species, is due to the large number of larvae produced by the gravid female and the magnitude of the immune response to different stages of the parasite [20]. *Trichinella* infection in all affected hosts, including humans, passes through two phases: the intestinal phase and the muscular phase. Subsequent complications, such as cardiac or neurological problems, result from the aggressive pathogenesis caused by the larval stages and may lead to a fatal outcome [10, 20].

Benzimidazoles, such as albendazole and mebendazole, are the most common anti-helminthics used in the management of *T. spiralis* infection. Albendazole has an advantage over mebendazole as its recommended plasma levels are achieved in most patients, so it does not require any monitoring [10]. Both drugs are characterized by a limited bioavailability, a high degree of resistance, and weak action against encysted larvae [7]. In addition to its anti-helminthic activity, albendazole has been found to have an anti-angiogenic effect in both cancerous and non-cancerous models of angiogenesis. These effects are mediated, partially, by a decrease in the level of vascular endothelial growth factor (VEGF) and the downregulation of VEGF-2 receptors [22]. VEGF plays an important role in the pathological process of angiogenesis during inflammation or cancer [26].

VEGF is upregulated during *T. spiralis* infection to provide the necessary nourishment and maintain *T. spiralis* larval stages within affected muscles [15]. Pro-angiogenic factors are secreted by a variety of immune cells, including mast cells. These factors play a key role in the termination of the intestinal phase, and thus the infection, by helping the host expel adult worms within 2 weeks of infection by developing what is called “intestinal mastocytosis” [5, 18, 28]. It was previously reported that the persistence of *T. spiralis* infection results from the late emergence of intestinal mast cells and the related inflammation [1]. Immunization has been reported to accelerate rapid expulsion through augmenting the intestinal mast cell population [3]. Therefore, hypothetically, mast cell stabilizers may negatively affect expulsion in both primary and challenge infection and thus support the maintenance of *T. spiralis* infection.

Mast cell stabilizers (MCs) are common medications that are known to decrease the degranulation of mast cells, thus preventing the release of histamine and other chemotactic factors [27]. Ketotifen is a MCS that also has antihistamine properties and is used in the treatment of a wide range of allergic and inflammatory disorders [2]. The present study explores the effect of the MCS ketotifen on the inflammatory response during the intestinal and muscular phases related to both primary and secondary experimental *T. spiralis* infection. We also investigated the effect of ketotifen on albendazole and the process of angiogenesis accompanying the nurse cell formation using VEGF as a marker for angiogenesis.

Methods

Ethical considerations

The current study was conducted according to the national and international guidelines on animal research and followed the strict quality measures of the Animal Center of the Theodor Bilharz Research Institute (TBRI) and guidelines of Animal Research: Reporting of In Vivo Experiments (ARRIVE) (https://arriveguidelines.org/).

Experimental animals and infection

A total of 56 female BALB/c mice, aged 6 to 8 weeks and weighing 25–30 g each, were obtained from the Animal Center of the TBRI. The animals were housed in accordance with the well-organized rearing TBRI laboratory system at a temperature of 22 ± 2 °C, an accurate light/dark photocycle, and relative humidity of about 55%. The *T. spiralis* strain used for the infection was obtained from the same animal center. Non-sensitized mice were infected orally with 200 ± 10 larvae/mouse. The process of animal infection was initiated by mincing pieces of heavily infected diaphragms, followed by digestion in 1% pepsin-hydrochloride, and then incubation overnight at 37 °C. Using the sedimentation technique, larvae were collected, washed in physiological saline (0.85%) 4 times, counted, and then stored for further usage in oral infection [9].

Sensitization

A small dose infection strategy was used to sensitize the mice [19]. Initial primary infection was obtained by infecting the animals orally with 10 larvae, followed infection with another 10 larvae after 1 week. Then, after another 2 weeks, challenge infection was completed by infecting the mice with an oral *T. spiralis* dose of 200 ± 10 larvae/mouse. Similarly, non-sensitized mice were infected with doses of 200 ± 10 *T. spiralis* larvae/mouse (primary infection).

Study groups

Infected mice were divided into sensitized (I) and non-sensitized (II) groups. Each group was subdivided into two other groups, the intestinal (A) and the muscular...
phases (B). These groups were further subdivided into four subgroups (a, b, c, and d), with each subgroup including seven mice, as follows:

- Groups IAa and IBa: non-sensitized, infected, non-treated (NS control groups [NS-C]).
- Groups IAb and IBB: non-sensitized, infected, treated with albendazole only (NS-ALB).
- Groups IAc and IBc: non-sensitized, infected, treated with MCS only (NS-MCS).
- Groups IAd and IBd: non-sensitized, infected, treated with albendazole and MCS (NS-ALB + MCS).

- Groups IIAa and IIBa: sensitized, infected, non-treated (S control groups [S-C]).
- Groups IIAb and IIBb: sensitized, infected, treated with albendazole only (S-ALB).
- Groups IIAc and IIBc: sensitized, infected, treated with MCS only (S-MCS).
- Groups IIAd and IIBd: sensitized, infected, treated with albendazole and MCS (S-ALB + MCS).

**Medicinal agents**

Albendazole (Bendax) was purchased and prepared as a 20 mg/ml suspension (Sigma Pharmaceutical Industries, Menofia, Egypt). A dose (50 mg/kg) of albendazole was given orally from the second day post-infection (dpi) for the following 3 days. Following Zhu et al. [32], pure powder of ketotifen was dissolved in carboxymethylcellulose sodium 0.5% w/v in saline and given orally (1 mg/kg/day). Mice were treated with MCS 2 days pre-infection and then once daily until the end of the experimental study. At the end of experiments, the mice in all groups were anesthetized with 5% of isoflurane vapor until sedation and then euthanized by cervical dislocation [13]. Muscles and intestine were collected from all mice.

**Parasitological analysis**

The parasite load was calculated by counting the number of adult worms in the intestine on 7 dpi and the number of larvae in the muscles on 40 dpi. The parasite load during the intestinal phase of infection was determined by counting adult parasites according to Wakelin and Lloyd [31]. Mice were euthanized on 7 dpi, following which the small intestines were isolated and washed in physiological saline. The specimens were then dissected into 1-cm segments and the segments incubated in physiological saline for 2 h at 37 °C. The segments were then washed three times and the supernatant from each was collected and centrifuged at 2000 rpm for 3 min. The number of adults in the sediment was counted under the inverted microscope at low-power magnification (×100) and calculated per 100 ml intestinal fluid. Similarly, larvae in the muscle specimens were counted according to Dunn and Wright [9].

**Histopathological examination**

To study the effect of the above treatments on the intestinal phase, we used a 1-cm piece of tissue from the small intestine, taken at the junction of the proximal one-third and distal two-thirds, from each mouse that was sacrificed on 7 dpi. For the muscle phase, skeletal muscle specimens from the diaphragm and the hind legs were isolated from mice that were sacrificed on 40 dpi. All specimens were fixed in 10% formalin, dehydrated, and embedded in paraffin blocks; the blocks were sliced into 5-µm-thick sections, and the sections stained by hematoxylin and eosin and examined under the microscopic at ×100 magnification.

**Immunohistochemistry and image analysis**

Tissue sections (5 µm thick) were deparaffinized in xylene and then rehydrated through a descending series of alcohol. These sections were then incubated in 3% hydrogen peroxide for 5 min to block endogenous peroxidase activity, followed by two washes of 5 min each in phosphate-buffered saline (PBS). The tissue sections were then immersed in 0.01 mol/l citrate buffer (pH 6) in a water bath for antigen retrieval, followed by incubation with the primary antibody murine anti-human VEGF monoclonal antibodies (Dako North America Inc., Carpinteria, CA, USA) for 1 h at room temperature. Later, the sections were washed three times in PBS for 15 min. Biotinylated goat anti-polyvalent secondary antibody and streptavidin peroxidase enzyme were added to the tissue samples for 10 min, followed by another wash in PBS. Peroxidase activity was visualized by the chromogenic substrate for peroxidase, diaminobenzidine (DAB), as described by Ramos-Vara and Miller [23]. Hematoxylin counterstain was used after washing the sections, followed by dehydration. These tissue sections were then cleared in xylene and mounted on slides with DPX. A brownish immunostaining for VEGF was considered to be positive, in comparison to the gray coloration of negative samples. The internal negative and positive control samples were provided within the kit to validate the results. To quantitatively estimate the local expression of VEGF, a specific analysis was performed using the Leica Qwin 500 Image Analyzer (LEICA Imaging Systems Ltd., Cambridge, UK). Optical density and area percentage were automatically calculated in 10 fields on a real-time image from the microscope that was connected to a video monitor.
Statistical analysis
The statistical significance was evaluated at $P<0.05$. One-way analysis of variance was applied to compare the means and standard deviations of the different study groups. The Tukey–Kramer post-hoc test was used to determine the mean differences and statistical significances between the results of the various treatment groups.

Results
Sensitization decreased parasite load during subsequent *T. spiralis* infection during both the intestinal and muscular phases
In infected non-sensitized and non-treated mice (the NS-control group; group IAAa), the adult intestinal worm count was 76.0±3.12/100 ml intestinal fluid. In comparison, in the sensitized control group (group IIAAa), the count was significantly reduced by 24.6% (57.3±2.18/100 ml) (Fig. 1a). The reduction in parasite count was even more pronounced during the muscular stage of infection (by 76.44%), where the larval count in the sensitized group (Group IIBa) was 14.3±2.65/g muscle tissue as compared to 60.7±7.05/g in the non-sensitized group (group IBAa) (Fig. 1b).

MCS reduced intestinal worm burden more efficiently in sensitized mice than in non-sensitized mice, while in the muscle phase, it was more effective in reducing the larval load in non-sensitized mice
In non-sensitized mice receiving MCS only (group IAC), the adult intestinal count was 56.7±6.61/100 ml intestinal fluid, which is a reduction of 25.39% compared to the control non-sensitized group. Sensitized mice receiving MCS only had an intestinal count of 38.7±6.14/100 ml, which is a 32.46% reduction compared to the control sensitized group (group IIAAa).

During the muscle phase, the non-sensitized group that received MCS only (group IBC) had a larval count of 26.7±1.32/g muscle tissue, which is a 56.01% reduction compared to the larval count in the control non-sensitized group (group IBAa). In comparison, sensitized mice receiving MCS only (group IIBC) had a larval count of 8.0±0.87/g, which is a 44.06% reduction compared to the control sensitized group (group IIBa).

The addition of MCS to albendazole did not significantly improve the reduction in parasite load achieved by albendazole alone
The administration of albendazole led to a significant decrease in the number of adult worms in both sensitized and non-sensitized mice. The adult worm count in non-sensitized mice treated with albendazole (group IAB) was 1.33±1/100 ml intestinal fluid, which is a 98.25% reduction from the control non-sensitized group (group IAAa) (Fig. 2a). In the sensitized group (group IIAa), the adult intestinal count in albendazole-treated mice was 0.67±0.50/100 ml, reflecting a reduction of 98.8% compared to control sensitized mice (group IIAa). In non-sensitized mice receiving both albendazole and MCS (group IAD), the adult intestinal count was 0.67±0.50/100 ml. In sensitized mice receiving
both drugs (group IIAd), the adult worm count was 0.67 ± 0.50/100 ml (Fig. 2b). In both non-sensitized and sensitized groups, the effect produced by the administration of both drugs was not significantly different from the effect produced by albendazole alone (P = 1.0 in both groups).

During the muscle phase, albendazole treatment significantly decreased the larval count in both sensitized and non-sensitized mice. The number of larvae in non-sensitized mice treated with albendazole (group IBb) was 3.33 ± 1.32/g muscle tissue, constituting a 94.51% reduction from the larval count in the control non-sensitized group (group IBa) (Fig. 2c). In the sensitized group (group IIBb), the encysted larval count in albendazole-treated mice was 1.0 ± 0.87/g, which is a reduction of 93.01% compared to the control sensitized mice (group IIBa) (Fig. 2d). The larval count in mice receiving both albendazole and MCS was 0.33 ± 0.5/g in both sensitized and non-sensitized mice. In both non-sensitized and sensitized groups, the effect produced by the administration of both drugs was not significantly different from the effect produced by albendazole alone (P = 0.32 and P = 1.0, respectively).

Effect of different drug regimens on the local inflammatory response

**Intestinal phase**

The intestinal tissue sections from infected, non-treated mice showed fragmentation and dense eosinophilic infiltration (Fig. 3a). The isolated intestinal specimens from albendazole-treated mice either sensitized or not showed a moderate improvement in intestinal pathology with persistent eosinophilic infiltration (Fig. 3b, c). The specimens derived from mice treated with MCS (sensitized or non-sensitized) showed a slight improvement in intestinal pathology with reduced eosinophilic infiltration (Fig. 3d, e). The histological analysis of the intestinal specimens from the combined albendazole and MCS group showed a significant reduction in eosinophilic infiltration compared to the control infected non-treated mice (Fig. 3f).

![Boxplot comparing the effect of different drug regimens showing the means and interquartile ranges of parasite load in both non-sensitized and sensitized mice.](image)

**Fig. 2** Boxplot comparing the effect of different drug regimens showing the means and interquartile ranges of parasite load in both non-sensitized and sensitized mice. **a** Intestinal worm count/100 ml intestinal fluid in non-sensitized mice. **b** Intestinal worm count/100 ml intestinal fluid in sensitized mice. **c** Muscle larval count/g muscle tissue in non-sensitized mice. **d** Muscle larval count/g muscle tissue in sensitized mice. Asterisk indicates significant difference at P < 0.05 (one-way ANOVA followed by Tukey–Kramer post-hoc comparison test). Abbreviations: ALB, Albendazole monotherapy group; AM, combined albendazole and MCS group; C, control infected non-treated mice; MCS, mast cell stabilizer monotherapy group; NS, Non-sensitized mice; S, sensitized mice.
non-sensitized) displayed mild inflammation and moderate disturbance of the intestinal epithelium (Fig. 3d, e). The tissue sections from mice in the combined regimen groups (receiving albendazole and MCS), both sensitized and non-sensitized, showed mild inflammation and an almost healthy intestinal epithelium (Fig. 3f, g).

**Muscle phase**

Muscle sections from control, infected, non-sensitized mice (Fig. 4a, b) showed intact larval stages inside several cystic lesions surrounded by moderate inflammation with the absence of inflammatory cells inside the cystic lesion.

Muscle sections from mice in the sensitized, control groups (Fig. 4c, d) showed a relatively intense inflammatory response, expressed by areas rich in eosinophils. Some intact larvae were seen, while others were fragmented and surrounded by an intense inflammatory reaction.

Sections from non-sensitized mice treated with MCS monotherapy (group IBc) showed both intact and degenerated larvae, with few inflammatory cells around the cystic lesions (Fig. 5a, b). Sensitized mice treated with MCS (group IIBc) only showed few cystic lesions, some intact larval stages, and areas with a complete absence of cystic larval lesions with few inflammatory cells, mainly monocytes (Fig. 5c, d).

Sections from non-sensitized mice receiving both albendazole and MCS (group IBD) showed some larvae with features of degeneration and other larvae that were intact (Fig. 6a, b). The muscle tissue specimens displayed a relatively mild inflammatory response composed mainly of monocytes, accompanied with an improvement of the pathology and complete absence of larval encystation (Fig. 6c, d). Sections from non-sensitized mice treated with albendazole (group IBb) showed larval degeneration and moderate inflammation (Fig. 6e). Sections from sensitized mice receiving albendazole (group IIBb) showed larval degeneration surrounded by an intense inflammatory cellular infiltration, composed mainly of eosinophils (Fig. 6f).

**Effect of different drug regimens on VEGF expression**

Local expression of VEGF was detected in control non-sensitized mice (groups IAa and IBa) (16.8 ± 1.58/g muscle tissue). Sensitized mice (groups IIAa and IIBa) showed a higher expression of VEGF (22.5 ± 2.88/g). The administration of albendazole led to a significant
reduction in VEGF levels in both non-sensitized (7.5 ± 1.2/g) and sensitized mice (4.0 ± 0.76/g). Both of the non-sensitized and sensitized mice receiving MCS with or without albendazole did not show any expression of VEGF in infected muscle fibers (Fig. 7; Table 1).

Discussion

The immune response to trichinellosis is a complex interplay of innate and acquired humoral and cellular immune responses. Many immune effector cells play a dual role in protection and immunopathology during infection with Trichinella spp. The most notable immune cells playing a pivotal role during the primary and secondary infection with T. spiralis are eosinophils and mast cells [6].

In our study, primary infection with a low infective dose of 10 T. spiralis larvae resulted in partial protection against re-infection, as reflected by the significant decrease in the counts of adult worms during the intestinal phase and in larvae during the muscle phase. This protective effect was more pronounced during the muscle phase of infection, during which the reduction in larval count reached 76.44% in sensitized mice; in comparison, the reduction in intestinal worm count was 24.6% during the intestinal phase. Protection against secondary Trichinella infection is dose-dependent, as demonstrated by Murrell [19] who reported that infection with a low dose of T. spiralis larvae resulted in a boost of the immune response. Subsequent infection using variable doses (112, 500, 10,000, and 25,000 larvae, respectively) resulted in resistance to re-infection. Protection against re-infection is possibly mediated through mast cells, eosinophils, mucosal immunity, and humoral immunity [4]. Doligalska [8] stated that infection with T. spiralis in mice generates an anti-inflammatory Th-2-mediated response, which controls the effector mechanism operating in the intestine and is associated with pronounced intestinal mastocytosis, eosinophilia, and destruction of the intestinal epithelial layer during the expulsion of parasites.
from the gut. This author further stated that protection is dependent on a non-specific inflammatory reaction mediated by mast cells. Doligalska [8] used ketotifen as an anti-allergic compound and observed a greater worm burden, which is not in agreement with our results. This result led Doligalska [8] to conclude that interaction between effector leukocytes and antibodies was not effective, leading to her proposing that other mechanisms, not related to hypersensitivity or conventional inflammatory response, regulated the level of infection.

In our study, repeated infection with *T. spiralis* larvae after sensitization with a low dose infection resulted in a more pronounced immune response with prominent eosinophilic infiltration. Drug treatment, whether with albendazole or with MCS, resulted in a partial reduction of inflammation and improvement of tissue structure. The eosinophilic response is an established feature of parasitic diseases, including trichinosis, which explains the increased co-incidence of allergic manifestations [6].

Studies on mice deficient in interleukin (IL) 5 have shown that the role of eosinophils in the expulsion of adult *T. spiralis* is more prominent during secondary rather than during primary infection [29, 30]. In contrast, eosinophils have been shown to exert a cytotoxic effect on *T. spiralis* during primary infection by antibody-dependent cellular cytotoxicity [11]. Interestingly, eosinophils are known to play a supportive role in larval growth through the IL-4/STAT6 signaling pathways, which results in a suppressed local inflammation and enhanced larval nutrition and metabolism [14].

While ketotifen is well known for its action as a MSC, it is also reported to affect eosinophils by interfering with eosinophil chemotaxis, impeding cellular functions, and inducing eosinophil necrosis [12, 16]. A few studies have reported the inhibitory effect of ketotifen on mucosal mast cell hyperplasia and intestinal dysmotility of rats infected with *T. spiralis* [8, 25]. These interactions, together with its mast cell stabilizing effect, may
contribute to alleviation of the inflammatory response in parasitic diseases, as demonstrated in the current study.

During the muscle phase, *T. spiralis* larvae settle in skeletal muscle fibers by transforming themselves into nurse cells which become encysted inside a collagen capsule. The resulting complex *Trichinella* larvae nests require a growing supply of oxygen and nutrients, which is provided by the formation of new blood vessels. *Trichinella spiralis* is reported to induce angiogenesis through the induction of VEGF [21].

In the current study, infection with *T. spiralis* was found to be associated with a positive local expression of VEGF in skeletal muscle tissue in the non-sensitized, infected, non-treated group. The sensitized group showed significantly increased VEGF expression. A decrease in tissue expression of VEGF was observed in the albendazole-treated mice, while mice treated with MCS showed a complete absence of positive VEGF staining. Consistent with our findings, Kang et al. [15] reported that VEGF was expressed in muscle fibers of *T. spiralis*-infected mice, which provides the necessary blood supply to nourish and maintain *T. spiralis* larval stages within affected muscles. Mast cells are known to promote angiogenesis [17], which explains the increased expression of VEGF in sensitized as compared to non-sensitized mice, as demonstrated in the current study. The effect of ketotifen on granuloma size and new vessel formation was studied by Russo et al. [24] in Wistar rats. These authors observed a reduction in granuloma size and decreased angiogenesis, evidenced by a lower hemoglobin content, and decreased levels of tumor necrosis factor alpha. In the current study, decreased expression of VEGF was also observed in albendazole monotherapy. Pourgholami et al. [22] reported that an acute dose of albendazole demonstrated an anti-angiogenic effect by suppressing both hypoxia-inducible factors and VEGF.

**Conclusion**

In conclusion, sensitization with a low dose of *T. spiralis* larvae conferred a partial protective immunity against re-infection. Prevention of mast cell degranulation,
through the administration of ketotifen, reduced the parasite load and minimized the inflammatory reaction. The hypothesis of this research relied on the possibility of ketotifen, as a MCS, to negatively affect the desired outcomes of the secondary infection, which was expected to eliminate the adult parasites by removing intestinal mastocytosis, thus decreasing the number of larvae within the muscles. However, this was not the case in this study. Instead, groups receiving MCS were found to have significantly lower larval counts. To infer the reason behind such results, we explored the angiogenic process needed for nurse cell formation and found that the groups treated with MCS showed a 100% reduction in VEGF expression. Decreased angiogenesis

![Photographs of muscular tissue sections showing the results of immunohistochemical staining specific for VEGF. Magnification: ×100. Red arrows indicate positive VEGF expression around the cystic lesion and within the lesions (arrowheads), and black arrows point to degenerated larvae.](image)

**Fig. 7**

- **a** Positive expression for VEGF, within and around cysts in the control group of non-sensitized, infected, not treated mice (group IBa).
- **b** Positive expression for VEGF in sensitized, infected, not treated mice (group IIBa).
- **c** Expression of VEGF in groups treated with albendazole with only minimal expression around the cyst and almost complete absence of the protein within the cyst.
- **d-f** Negative expression in all groups treated with MCS: non-sensitized mice treated with MCS (Group IBc) (**d**), sensitized mice treated with MCS (Group IIBc) (**e**) and mice treated with combined therapy (**f**).
- **g** Mean expression levels of VEGF in skeletal muscle tissue (y-axis) of infected, control, sensitized and non-sensitized mice (x-axis). Significant difference at P < 0.05 (one-way ANOVA). Abbreviations: VEGF, Vascular endothelial growth factor

**Table 1** Vascular endothelial growth factor expression levels in skeletal muscle sections from the different study groups

| Study groups | Vascular endothelial growth factor expression in skeletal muscle tissue |
|--------------|-------------------------------------------------------------------------|
|              | Non-sensitized mice          | Sensitized mice                  |
|              | Mean   | Standard deviation | Mean   | Standard deviation |
| Infected control groups (groups IBa and IIBa) | 16.75  | 1.58              | 22.50  | 2.88              |
| Albendazole groups (groups IBb and IIBb) | 7.50*  | 1.20*             | 4.00*  | 0.76*             |
| MCS groups (groups IBc and IIBc) | 0.00*  | 0.00*             | 0.00*  | 0.00*             |
| Combined albendazole and MCS groups (groups IBd and IIBd) | 0.00*  | 0.00*             | 0.00*  | 0.00*             |

*MCS Mast cell stabilizer

*Significant difference to control at P < 0.05 (one-way analysis of variance)

* See “Study groups” section for complete description of treatments
can, partially, explain the reduction in muscle larval load since new vessel formation is an essential process in the formation of nest cells that nourish and support encysting larvae.

The anti-angiogenic effect of ketotifen also provides a protective effect against larval encystation during the muscle phase. As such, it can be of value as an adjuvant drug in conventional anti-helminthic therapy in the management of *T. spiralis* infection. The anti-angiogenic potential of albendazole suggests that the action of this anti-helminthic during *T. spiralis* infection is not confined to the structural damage of the parasite cuticle, but extends to affect the host immunopathological response, while still requiring an adjuvant such as MCS to synergize with its immune-mediated action.

Acknowledgements
Not applicable.

Authors’ contributions
MAED and AsmalaAA contributed to the conception and study design. MSAA and MES contributed to the editing and reviewing of the intellectual contents. SEA and ASA were responsible for the literature search and the experimental and clinical applications. MAH, SEA, and MAED contributed to the data acquisition. AmnYAAA and MB were responsible for the statistical analysis. MAED and BAK contributed to the data analysis, manuscript preparation, editing, and reviewing. MAED acts as a guarantor and corresponding author. All authors read and approved the final manuscript.

Funding
This study is not funded.

Availability of data and materials
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The current study was conducted according to the national and international guidelines of the animal research and followed the strict quality measures of the Animal Center of the Theodor Bilharz Research Institute (TBRRI).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medical Parasitology, Faculty of Medicine, Fayoum University, Fayoum, Egypt. 2 Department of Medical Parasitology, Faculty of Medicine, Cairo University, Giza, Egypt. 3 Department of Postgraduate Studies & Scientific Research, Armed Forces College of Medicine (AFCM), Cairo, Egypt. 4 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt. 5 Department of Pathology, National Research Center, Giza, Egypt. 6 Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt. 7 Department of Anatomy & Embryology, Faculty of Medicine, Cairo University, Giza, Egypt. 8 Department of Anatomy, Jouf University, Sakaka, Saudi Arabia.

Received: 28 June 2021 Accepted: 18 October 2021 Published online: 06 November 2021

References
1. Alizadeh H, Murrell KD. The intestinal mast cell response to *Trichinella spiralis* infection in mast cell-deficient w/wv mice. J Parasitol. 1984;70(5):767–73.
2. Ang DC, Hilligoss J, Stump T. Mast cell stabilizer (Ketotifen) in fibromyalgia: phase I randomized controlled clinical trial. Clin J Pain. 2015;31(9):836–42. https://doi.org/10.1097/AJP.0000000000000169.
3. Bell R, McGregor DD. Rapid expulsion of *Trichinella spiralis* co-infection by using antigenic extracts of larvae and intestinal stimulation with an unrelated parasite. Infect Immun. 1980;29(1):194–9. https://doi.org/10.1128/IAI.29.1.194-199.1980.
4. Bi K, Yang J, Wang L, Gu Y, Zhan B, Zhu X. Partially protective immunity induced by a 20 kDa protein secreted by *Trichinella spiralis* stichocytes. PLoS ONE. 2015;10(8): e0136189. https://doi.org/10.1371/journal.pone.0136189.
5. Blum LR, Thrasher SM, Gagliardo LF, Fabre V, Appleton J. Expulsion of secondary *Trichinella spiralis* infection in rats occurs independently of mucosal mast cell release of mast cell protease II. J Immunol. 2009;183:5816–22. https://doi.org/10.4049/jimmunol.0900944.
6. Bruschi F, Korenaga M, Watanabe N. Eosinophilins and *Trichinella* infection: toxic for the parasite and the host? Trends Parasitol. 2008;24(10):462–7. https://doi.org/10.1016/j.pt.2008.07.001.
7. Caner A, Dözykaya M, Değirmenci A, Can H, Baykan S, Üner A, et al. Comparison of the effects of Artemisia vulgaris and *Artemisia absinthium* growing in western Anatolia against trichinellosis (*Trichinella spiralis*) in rats. Exp Parasitol. 2008;119(1):173–9. https://doi.org/10.1016/j.expara.2008.01.012.
8. Dolgiliskä M. Effect of ketotifen on the immune response in BALB/c mice infected with *Trichinella spiralis*. Wad Parazitol. 2000;46(2):217–24.
9. Dunn LJ, Wright KA. Cell injury caused by *Trichinella spiralis* in the mucosal epithelium of B10A mice. J Parasitol. 1985;71(6):757–66.
10. Gottstein B, Pozio E, Nöckler K. Epidemiology diagnosis treatment and control of trichinellosis. Clin Microbiol Rev. 2009;22(1):127–45. https://doi.org/10.1128/CMR.00026-08.
11. Gurish MF, Humbles A, Tao H, Finkelstein S, Boyce JA, Gerard C, et al. CCR3 is required for tissue eosinophilia and larval cytotoxicity after infection with *Trichinella spiralis*. J Immunol. 2002;168(11):5730–6. https://doi.org/10.4049/jimmunol.168.11.5730.
12. Hasala H, Malm-Erfelt M, Erfelt J, Giembycz MA, Zhang X, Molianen E, et al. Ketotifen induces primary necrosis of human eosinophils. J Ocul Pharmacol Ther. 2005;21(4):318–27. https://doi.org/10.1089/jop.2005.21.318.
13. Hickman DL, Johnson SW. Evaluation of the aesthetics of physical methods of euthanasia of anesthetized rats. J Am Assoc Lab Anim Sci. 2011;50(5):695–701.
14. Huang L, Beiting DP, Gebreselasie NG, Gagliardo LF, Ruyechan MC, Lee NA, et al. Eosinophilins and IL-4 support nematode growth coincident with an innate response to tissue injury. PLoS Pathog. 2015;11(12):e1005347. https://doi.org/10.1371/journal.ppat.1005347.
15. Kang YJ, Jo JO, Cho MK, Yu HS, Ock MS, Cha HJ. *Trichinella spiralis* infection induces angiogenic factor thrombin β4 expression. Vet Parasitol. 2011;181(2–4):222–8. https://doi.org/10.1016/j.vetpar.2011.03.058.
16. Lanz R, Woerly G, Loiseau S, Loyens M, Schoch C, Capron M. Inhibition of human eosinophil functions by ketotifen in vitro. Invest Ophthalmol Vis Sci. 2003;44(13):1294. https://doi.org/10.1126/BOI.197.2346.
17. Longo V, Tamina R, Brunotti O, Piconti S, Argentiero A, Silvestri N, et al. Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. Clin Exp Med. 2008;18:319–23. https://doi.org/10.1016/j.cem.2008.01.049-93.
18. Mostafa EM, Atwa HA. Intestinal mastocytosis in *Trichinella spiralis* infection: immunohistochemical study in murine model. Parasitol United J. 2020;31(1):52–9. https://doi.org/10.21668/pjau.2020.24540.1060.
19. Murrell KD. *Trichinella spiralis* acquired immunity in swine. Exp Parasitol. 1985;59(3):347–54. https://doi.org/10.1016/0014-4898(85)90090-6.
20. Nada SM, Mohammad SM, Moaad HSF, El-shafey MA, Al-Ghandour AMF, Ibrahim N. Therapeutic effect of *Nigella sativa* and ivernemcin versus albendazole on experimental trichinellosis in mice. J Egypt Soc Parasitol. 2018;48(1):85–92.
21. Ock MS, Cha HJ, Choi YH. Verifiable hypotheses for thymosin β4-dependent and -independent angiogenic induction of Trichinella spiralis-triggered nurse cell formation. Int J Mol Sci. 2013;14(12):23492–8. https://doi.org/10.3390/ijms141223492.

22. Pourgholami MH, Khachigian LM, Fahmy RG, Badar S, Wang L, Chu SW, et al. Albendazole inhibits endothelial cell migration, tube formation, vasopereumability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. Biochem Biophys Res Commun. 2010;397(4):729–34. https://doi.org/10.1016/j.bbrc.2010.06.019.

23. Ramos-Vara JA, Miller MA. When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry—the red, brown, and blue technique. Vet Pathol. 2014;51(1):42–87. https://doi.org/10.1177/0300985813505879.

24. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037–43.

25. Serna H, Porras M, Vergara P. Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat. J Pharmacol Exp Ther. 2006;319(3):1104–11. https://doi.org/10.1124/jpet.106.104620.

26. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097–105. https://doi.org/10.1177/1947601911423031.

27. Stephen J, Chadwick MD, Facs FAAOA. Principles of allergy management. In: Krouse JH, Derebery MJM, Chadwick SJ, editors. Managing the allergic patient. Philadelphia: Elsevier Saunders; 2008. p. 19–72. https://doi.org/10.1016/B978-1-4160-3677-7.X5001-8.

28. Thrasher SM, Scalfone LK, Holowka D, Appleton JA. In vitro modelling of rat mucosal mast cell function in Trichinella spiralis infection. Parasitol Immunol. 2013;35(1):21–31. https://doi.org/10.1111/pim.12014.

29. Vallance BA, Blennerhassett PA, Deng Y, Matthaei KJ, Young IG, Collins SM. IL-5 contributes to worm expulsion and muscle hypercontractility in a primary T. spiralis infection. Am J Physiol. 1999;277(2):G400–8. https://doi.org/10.1152/ajphysiol.1999.277.2.G400.

30. Vallance BA, Matthaei KJ, Sanovic S, Young IG, Collins SM. Interleukin-5 deficient mice exhibit impaired host defence against challenge Trichinella spiralis infections. Parasite Immunol. 2000;22(10):487–92. https://doi.org/10.1046/j.1365-3024.2000.00328.x.

31. Wakelin D, Lloyd M. Accelerated expulsion of adult Trichinella spiralis in mice given lymphoid cells and serum from infected donors. Parasitology. 1976;72(3):307–15. https://doi.org/10.1017/S0031182000049507.

32. Zhu TH, Zou G, Ding SJ, Li TT, Zhu LB, Wang JZ, et al. Mast cell stabilizer ketotifen reduces hyperalgesia in a rodent model of surgically induced endometriosis. J Pain Res. 2019;12:1359–69. https://doi.org/10.2147/JPR.S195909.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.